<?xml version="1.0" encoding="UTF-8"?>
<p>As COVID-19 causes substantial lung damage, antifibrotics, senolytics and other geroprotectors may be explored in clinical trials to assist in patient recovery to prevent a reduction in respiratory function.</p>
